The Trump administration’s promised direct-to-consumer drug platform TrumpRx has officially gone live, with President Trump ...
This year at CES, the atmosphere felt noticeably different. Instead of leading with spectacle, many companies focused on ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking ...
TAIPEI, Feb 4 (Reuters) - A surge in demand for artificial intelligence applications is straining supply chains and driving ...
Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and ...
Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...
The small rocket and capsule have been flying since April 2015 and have combined to make 38 launches, all but one of which ...
Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film February 2, 2026 8:00 ...
Highguard is pushing out a massive update tomorrow for Episode 2, bringing tons of new core content despite initial backlash.
Axon Neuroscience’s active tau immunotherapy, AADvac1, has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Phase 2 Alzheimer’s disease clinical trial, while ...
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...
The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results